EHA 2014 | CLL Treatment and Research News

EHA 2014

How New CLL Medicines May Leave No Patient Behind

Dr. Barbara Eichhorst, a noted CLL expert from Cologne, Germany feels the latest news on promising therapies for the illness should be of help to a wide group of patients, including those with the most aggressive forms of the disease.

New hope for CLL patients

How the New Paradigm of Treatment Offers Hope to a Wide Range of CLL Patients

Dr. Stephan Stilgenbauer, an expert in CLL from Ulm, Germany, explains the new age of care for a wide range of patients, including those with the most aggressive versions of the disease.

Positive news for CLL patients from EHA 2014

What’s Next for CLL Patients – Positive News from EHA 2014

Professor John Gribben from Bart’s Hospital in London explains why he is excited about promising new treatments for patients with chronic lymphocytic leukemia (CLL) including the latest on trials in ibrutinib, idelalisib, and ABT199.

Advances in oral CLL therapy research

Advances in Oral CLL Therapy Research

Dr. Peter Hillmen, a CLL expert from Leeds University in the UK, shares research highlights from the 2014 European Hematology Association (EHA) meeting. Dr. Hillmen explores advances in oral CLL treatment, including ibrutinib (Imbruvica), as well as developing oral therapies idelalisib and ABT-199.

Update on ABT199 in CLL

Update on ABT199 in CLL

Speaking to Patient Power from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour from Sir Peter MacCallum, Department of Oncology, Australia, outlines the three presentations at the meeting updating clinicians on the latest findings with ABT199 , an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor.

Join Our Community Register for Events Read Our Latest Blog

Page last updated on September 9, 2014